251 related articles for article (PubMed ID: 19317653)
21. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
Høgdall CK; Nørgaard-Pedersen B; Mogensen O
Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
[TBL] [Abstract][Full Text] [Related]
22. [Epithelial ovarian cancer--preoperative assessment of Ca 125 levels as an independent prognostic factor].
Ivanov S; Ivanov S
Akush Ginekol (Sofiia); 2003; 42(3):16-9. PubMed ID: 12858485
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
24. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
25. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
26. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.
Nagele F; Petru E; Medl M; Kainz C; Graf AH; Sevelda P
Obstet Gynecol; 1995 Aug; 86(2):259-64. PubMed ID: 7617357
[TBL] [Abstract][Full Text] [Related]
27. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
Sevinc A; Camci C; Turk HM; Buyukberber S
Oncology; 2003; 65(1):1-6. PubMed ID: 12837976
[TBL] [Abstract][Full Text] [Related]
28. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
29. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
30. [Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma].
Kokocińska D; Worwag J; Tomala J; Dzieciuchowicz L; Nowak S; Kuśmierski S
Ginekol Pol; 1994 Sep; 65(9):495-501. PubMed ID: 7721162
[TBL] [Abstract][Full Text] [Related]
31. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
[TBL] [Abstract][Full Text] [Related]
32. Ascites as a predictor of ovarian malignancy.
Shen-Gunther J; Mannel RS
Gynecol Oncol; 2002 Oct; 87(1):77-83. PubMed ID: 12468346
[TBL] [Abstract][Full Text] [Related]
33. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
[TBL] [Abstract][Full Text] [Related]
34. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
Hefler L; Tempfer C; Heinze G; Mayerhofer K; Breitenecker G; Leodolter S; Reinthaller A; Kainz C
Br J Cancer; 1999 Nov; 81(5):855-9. PubMed ID: 10555758
[TBL] [Abstract][Full Text] [Related]
35. [Cancer antigen CA 125 in ovarian cancer].
Debniak J; Stukan M; Pietrzak-Stukan M; Klasa-Mazurkiewicz D
Ginekol Pol; 2003 Sep; 74(9):701-9. PubMed ID: 14674111
[TBL] [Abstract][Full Text] [Related]
36. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
Meden H; Rath W; Teichmann A; Kuhn W
Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
[TBL] [Abstract][Full Text] [Related]
37. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
38. [Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients].
Grabiec M; Nowicki P; Walentowicz M; Greźlikowska U; Mierzwa T; Chmielewska W
Ginekol Pol; 2005 May; 76(5):371-6. PubMed ID: 16145856
[TBL] [Abstract][Full Text] [Related]
39. Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma.
Gronlund B; Dehn H; Høgdall CK; Engelholm SA; Jørgensen M; Nørgaard-Pedersen B; Høgdall EV
Int J Gynecol Cancer; 2005; 15(5):836-43. PubMed ID: 16174233
[TBL] [Abstract][Full Text] [Related]
40. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]